GABAA Receptor Subtype‐Selective Efficacy: TPA023, an α2/α3 Selective Non‐sedating Anxiolytic and α5IA, an α5 Selective Cognition Enhancer
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
TPA023 and α5IA are structurally related compounds that selectively modulate certain GABA A receptor subtypes. Hence, TPA023 has weak partial agonist efficacy at the α2 and α3 subtypes whereas α5IA has inverse agonist efficacy at the α5 subtype. These efficacy characteristics translate into novel pharmacological profiles in preclinical species with TPA023 being a nonsedating anxiolytic in rats and primates whereas α5IA enhanced cognition in rats but was devoid of the proconvulsant or kindling liabilities associated with nonselective inverse agonists. In vitro and in vivo metabolic studies showed that TPA023 was metabolized via CYP3A4‐mediated t‐butyl hydroxylation and N‐deethylation whereas α5IA was metabolized to produce the hydroxymethyl isoxazole, the latter of which was highly insoluble and caused renal toxicity in preclinical species. In humans, TPA023 had a half‐life in the region of 6–7 h whereas the half‐life of α5IA was 2–2.5 h. TPA023 was clearly differentiated from the nonselective agonist lorazepam in terms of saccadic eye movement and unlike lorazepam, it did not impair either postural stability, as judged by body sway, or cognition. The occurrence of the hydroxymethyl isoxazole metabolite of α5IA in human urine precluded the use of α5IA in prolonged dosing studies. Nevertheless, α5IA was evaluated in an alcohol‐induced cognitive impairment model in healthy normal volunteers and was found to reverse the memory‐impairing effects of alcohol. To date, however, no efficacy data for either TPA023 or α5IA in patient populations has been reported, although at the very least, the preclinical and limited clinical data with TPA023 and α5IA validate the approach of targeting specific GABA A receptors through subtype‐selective efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fritschy, J., & Mohler, H. (1995) · Journal of Comparative Neurology · doi:10.1002/cne.903590111 · Cited by 1,244
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Self-citationCollinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05572.2002 · Cited by 628 · cited 3×
“2002) demonstrated improved performance in certain cognitive tasks (Collinson et al. 2002; Crestani et al. 2002).”
BackgroundSelf-citationAnalysis of the set of GABAA receptor genes in the human genome
Simon, J., Wakimoto, H., Fujita, N., Lalande, M., & Barnard, E. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401354200 · Cited by 253 · cited 1×
“The GABAA receptor is a pentameric assembly of subunits derived from the GABAA gene family (α1–6, β1–3, γ 1– 3, δ, ∈, θ and π ; Simon et al. 2004) and is responsible for the ligand (GABA)-gated flow of chloride ions into the neuron, which result in a hyperpolarization of the cell membrane that…”
BackgroundDias, R., Sheppard, W. F. A., Fradley, R. L., Garrett, E. M., Stanley, J. L., Tye, S. J., Goodacre, S., Lincoln, R. J., Cook, S. M., Conley, R., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1166-05.2005 · Cited by 247
Self-citationRowlett, J. K., Platt, D. M., Lelas, S., Atack, J. R., & Dawson, G. R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405621102 · Cited by 212
Self-citationde Haas, S. L., de Visser, S. J., van der Post, J. P., de Smet, M., Schoemaker, R. C., Rijnbeek, B., Cohen, A. F., Vega, J. M., Agrawal, N. G. B., Goel, T. V., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106072343 · Cited by 84 · cited 4×
“…are clearly differentiated from lorazepam and whereas it may be tempting to speculate that the similar effects of TPA023 and lorazepam on saccadic peak velocity may be a surrogate of anxiolytic efficacy (de Haas et al. 2007)— 32 CNS Neuroscience & Therapeutics 14 (2008) 25–35 c© 2008 The Author.”
BackgroundMethodInfluentialAtor, N. A. (2005) · CNS Spectrums · doi:10.1017/s1092852900009883 · Cited by 59
Cited by
The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders
Braat, S., & Kooy, R. F. (2015) · Neuron · doi:10.1016/j.neuron.2015.03.042 · Cited by 294
The Benzodiazepine Binding Sites of GABAA Receptors
Sigel, E., & Ernst, M. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.006 · Cited by 287
Regulation of GABAA Receptor Subunit Expression by Pharmacological Agents
Uusi-Oukari, M., & Korpi, E. R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002063 · Cited by 213
Buchanan, R. W., Keefe, R. S. E., Lieberman, J. A., Barch, D. M., Csernansky, J. G., Goff, D. C., Gold, J. M., Green, M. F., Jarskog, L. F., Javitt, D. C., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.052 · Cited by 172
Current use of benzodiazepines in anxiety disorders
Cloos, J.-M., & Ferreira, V. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32831a473d · Cited by 127
Metadata
- Authors
- Atack, J. R.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2008-03
- Volume
- 14
- Issue
- 1
- Pages
- 25-35
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W2133671844
- Cited by
- 52
- References
- 10
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GABAA Receptor Subtype‐Selective Efficacy: TPA023, an α2/α3 Selective Non‐sedating Anxiolytic and α5IA, an α5 Selective Cognition Enhancer. https://app.cochat.ai/papers/10.1111/j.1527-3458.2007.00034.x
- The paper
- Atack, J. R. (2008). GABAA Receptor Subtype‐Selective Efficacy: TPA023, an α2/α3 Selective Non‐sedating Anxiolytic and α5IA, an α5 Selective Cognition Enhancer. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/j.1527-3458.2007.00034.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.